The Application Value Of F-18-Fdg Pet/Ct Imaging In The Gamma Knife Radiotherapy Of Lung Cancer Patients With Brain Metastases

This study aims to assess the effect of 18F-FDG PET/CT imaging on the short- and long-term prognoses of lung cancer patients with brain metastases after gamma knife radiotherapy. 104 lung cancer patients with brain metastases were divided into the PET/CT (n = 52) and control groups (n = 52). In the PET/CT group, 18F-FDG PET/CT imaging combined with gamma knife treatment was performed. Tumor targets were outlined and the prescription doses were determined based on the PET/CT findings during the gamma knife radiotherapy. In the control group, gamma knife treatment alone was given. The effective rates, local control rates, average survival times, and survival rates were compared. The preoperative and postoperative KPS scores at three months significantly differed in both groups (P = 0.000, 0.032). The clinical efficacy at postoperative three months significantly differed between the two groups (Z = -2.048, P < 0.05). In the PET/CT group, the effective rate at postoperative three months was 61.35% (32/52), significantly higher than the 42.30% (22/52) in the control group (P = 0.032). The local control rate significantly differed in the two groups [90.38% (47/52) vs. 75.00% (39/52); P = 0.038]. The average survival times were 14.2 and 12.2 months in the PET/CT and control groups (both P > 0.05). The incidence rate of acute and chronic adverse events was 21.15% in the PET/CT group, significantly lower than the 42.30% in the control group (P = 0.020). The application of F-18-FDG PET/CT enables a closer tumor target delineation to the tumor biological target volume and increases the localized radiation dose in the high metabolic area during gamma knife radiotherapy. F-18-FDG PET/CT imaging combined with gamma knife treatment is more efficacious and safer compared to gamma knife treatment alone.